Key clinical point: Prolonged treatment with proton pump inhibitors (PPI) is associated with a higher risk for type 2 diabetes (T2D), thus unnecessary prescription, particularly for long-term use, should be avoided.
Major finding: The risk for T2D was higher among patients receiving PPI for 8 weeks to 6 months (odds ratio [OR] 1.19; 95% CI 1.15-1.24), 6 months to 2 years (OR 1.43; 95% CI 1.38-1.49), and >2 years (OR 1.56; 95% CI 1.49-1.64) than those receiving PPI for <8 weeks ( Ptrend < .001), particularly among younger patients and those with worse clinical complexity.
Study details: Findings are from a nested case-control study including 777,420 patients aged ≥40 years who received PPI, of which 50,535 were diagnosed with T2D and matched with control participants.
Disclosures: The study was funded by the Italian Ministry of Education, University, and Research. G Corrao declared being an advisory board member, receiving research support, and participating in numerous projects funded by various sources.
Source: Ciardullo S et al. Prolonged use of proton pump inhibitors and risk of type 2 diabetes: Results from a large population-based nested case-control study. J Clin Endocrinol Metab. 2022 (Apr 16). Doi: 10.1210/clinem/dgac231